New hope for AML patients: can a Cancer-Fighting drug boost Chemo's power?
NCT ID NCT04214249
Summary
This study is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination helps more patients achieve a deep remission with no detectable cancer cells. Patients are randomly assigned to receive either the standard chemo alone or the standard chemo plus pembrolizumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298, United States
-
Wake Forest Baptist Health - Wilkes Medical Center
Wilkesboro, North Carolina, 28659, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
-
Wake Forest University at Clemmons
Clemmons, North Carolina, 27012, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.